# Submission rejected

## DRAFT REJECTED

**SPAR verdict:** `reject_critical` (3-0 unanimous reject).

## Proposed thesis (rejected)

> the loss of SIRT2 blunted the response of AMPK to metformin treatment in mice infused with Ang II and repressed the metformin-mediated reduction of cardiac hypertrophy and protection of cardiac function.

## Panel reviews

### `evidence_auditor` — `reject` (score 1)

The submission contains a critical failure in the citation trace for claim C023. The alias match for 'Loss' was resolved to 'AZASETRON', which is a completely unrelated pharmacological agent (a 5-HT3 receptor antagonist) and bears no relation to the loss of the SIRT2 protein discussed in the thesis and claims. This indicates a fundamental failure in the evidence trace process.

**Flagged claims:** C023

### `domain_skeptic` — `reject` (score 3)

The submission suffers from severe mechanism inflation and a critical failure in entity resolution. The claims extrapolate findings from a highly specific mouse model (Ang II-infused Sirt2 knockout mice) to broader conclusions about 'aging-related' cardiac hypertrophy [C023] without providing evidence that the Ang II model is a valid proxy for natural aging. This is a classic case of over-claiming where a specific pharmacological stressor is used to generalize a systemic biological process.

Furthermore, the citation trace reveals a catastrophic error in the underlying data processing: the term 'Loss' in claim C023 was resolved as an alias for 'AZASETRON'. Azasetron is a 5-HT3 receptor antagonist and has no biological equivalence to the genetic loss of the SIRT2 protein. This indicates that the evidence supporting C023 is fundamentally flawed or based on a hallucinated entity match, rendering the claim scientifically baseless within the provided context.

**Flagged claims:** C023

### `final_judge` — `reject` (score 1)

I align with both the Evidence Auditor and the Domain Skeptic. The submission contains a catastrophic failure in entity resolution where the term 'Loss' (referring to the genetic knockout of SIRT2) was mapped to 'AZASETRON', a 5-HT3 receptor antagonist. This is not a minor clerical error but a fundamental breakdown in the evidence trace, rendering the support for C023 completely invalid. 

Additionally, I concur with the Domain Skeptic regarding the over-generalization in C023. The jump from an Ang II-infused mouse model to 'aging-related' hypertrophy is an unsupported extrapolation. Given that the primary evidence trace is corrupted by a hallucinated alias match and the claims overreach the experimental scope, the submission cannot be accepted.

**Flagged claims:** C023
